Sunesis Pharmaceutic (SNSS) Stock Overview
USA - NASDAQ:SNSS -
SNSS Key Statistics, Chart & Performance
The current stock price of SNSS is 5.32 null. In the past month the price increased by 92.06%. In the past year, price decreased by -46%.
SNSS Latest News, Press Relases and Analysis
About SNSS
Company Profile
Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.
Company Info
Sunesis Pharmaceutic
395 OYSTER POINT BOULEVARD SUITE 400
SOUTH SAN FRANCISCO CA 94080
CEO: Dayton Misfeldt
Phone: 650-266-3500
Sunesis Pharmaceutic / SNSS FAQ
Can you describe the business of Sunesis Pharmaceutic?
Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.
Can you provide the latest stock price for Sunesis Pharmaceutic?
The current stock price of SNSS is 5.32 null. The price increased by 24.3% in the last trading session.
What is the dividend status of Sunesis Pharmaceutic?
SNSS does not pay a dividend.
How is the ChartMill rating for Sunesis Pharmaceutic?
SNSS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the ownership structure of Sunesis Pharmaceutic (SNSS)?
You can find the ownership structure of Sunesis Pharmaceutic (SNSS) on the Ownership tab.
SNSS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SNSS. When comparing the yearly performance of all stocks, SNSS is one of the better performing stocks in the market, outperforming 93.14% of all stocks.
SNSS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNSS. The financial health of SNSS is average, but there are quite some concerns on its profitability.
SNSS Financial Highlights
Over the last trailing twelve months SNSS reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS decreased by -7.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -18408.33% | ||
| ROA | -78.8% | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |